window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Biomica

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Evogene reports Phase 1 results for microbiome therapy BMC128 with nivolumab

    Evogene has reported positive Phase 1 data for microbiome-based therapy [...]

    June 8, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Evogene and Shanghai Lishan Biopharmaceuticals enter exclusive licensing agreement for BMC128

    Evogene Ltd and Shanghai Lishan Biopharmaceuticals Co. have entered into [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Evogene licenses microbiome cancer therapy BMC128 to Shanghai Lishan Biopharmaceuticals

    Evogene and Shanghai Lishan Biopharmaceuticals have entered into an exclusive [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Ten-year NHS study supports focal therapy for prostate cancer with fewer side effects
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Mission Therapeutics signs US$292M deal for acute kidney injury programme
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Research & Development
  • Medicus receives FDA feedback and IRB approval for Teverelix Phase 2 urinary retention trial
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top